XOMA SUSPENDS HEPEX-B WORK FOLLOWING CUBIST DECISION

XOMA Ltd. announced that, in light of Cubist Pharmaceuticals, Inc.'s recently announced decision to cease investment in its HepeX-B product because of stringent FDA requirements for regulatory approval, XOMA has placed its production process development work for Cubist on hold and has issued a notice of contract termination to Cubist. Cubist and XOMA have begun discussions to consider other development options for HepeX-B.
Genetic Engineering News